A federal appeals court preserved access to the
abortion pill mifepristone for now but reduced the period of pregnancy when the drug can be used and said it could not be dispensed by mail. The ruling late Wednesday temporarily narrowed a decision by a lower court judge in
Texas that had completely blocked the Food and Drug Administration’s approval of the nation’s most commonly used method of abortion. The Texas order unsettled abortion providers less than a year after the reversal of Roe v. Wade already dramatically curtailed abortion access. The case is likely to go to the U.S. Supreme Court. “We are going to continue to fight in the courts, we believe the law is on our side, and we will prevail,”
White House Press Secretary Karine Jean-Pierre said Thursday, speaking to reporters from
Dublin during a visit by President
Joe Biden. Mifepristone was approved for use by the FDA more than two decades ago and is used in combination with a second drug, misoprostol. In a far-reaching ruling last week, a federal judge blocked the FDA’s approval of the pill following a lawsuit by the drug’s opponents. There is virtually no precedent for a lone judge overturning the regulator’s medical recommendations. The ruling was put on pause to allow an appeal. Just before midnight Wednesday, the 5th U.S. Circuit Court of Appeals in New Orleans ruled that the FDA’s initial approval of mifepristone in 2000 could remain in effect. But in the 2-1 vote, the panel of judges put on hold changes made by the regulator since 2016 that relaxed the rules for prescribing and dispensing mifepristone. Those included extending the period of pregnancy when the drug can be used from seven weeks to 10, and also allowing it to be dispensed by mail, without any need to visit a doctor’s office. The two judges who voted to tighten restrictions, Kurt Engelhardt and Andrew Oldham, are both appointees of former President
Donald Trump. The third judge, Catharina Haynes, is an appointee of former President
George W. Bush. She said she would have put the lower court ruling on hold entirely for now to allow oral arguments in the case. Either side, or both, could take the case to the Supreme Court. Opponents of the drug could seek to keep the full lower court ruling in effect. The Biden administration, meanwhile, could ask the high court to allow all the FDA changes to remain in place while the case continues to play out. The appeals court judges in the majority noted that the Biden administration and mifepristone’s manufacturer “warn us of significant public consequences” that would result if mifepristone were withdrawn entirely from the market under the lower court ruling. But the judges suggested changes the FDA made making mifepristone easier to obtain since 2016 were less consequential than its initial approval of the drug in 2000. It would be “difficult” to argue the changes were “so critical to the public given that the nation operated — and mifepristone was administered to millions of
Women — without them for sixteen years” the judges wrote. When the drug was initially approved in 2000, the FDA limited its use to up to seven weeks of pregnancy. It also required three in-person office visits: the first to administer mifepristone, the next to administer the second drug misoprostol and the third to address any complications. It also required a doctor’s supervision and a reporting system for any serious consequences associated with the drug. If the appeals court’s action stands, those would again be the terms under which mifepristone could be dispensed for now.
Democratic leaders in states where abortion remains legal since the
Supreme Court overturned Roe v. Wade last year say they are preparing in case mifepristone becomes restricted.
New York Gov. Kathy Hochul said Tuesday that her state would stockpile 150,000 doses of misoprostol. The White House also has contingency plans in place, but Jean-Pierre held off on detailing them while the legal action continued. Instead, she detailed a proposed a new federal rule to limit how law enforcement and state officials collect medical records if they investigate women who flee their home states to seek abortions elsewhere. Pharmaceutical executives this week also signed a letter that condemned the Texas ruling and warned that FDA approval of other drugs could be at risk if U.S. District Judge Matthew Kacsmaryk’s decision stands. The lawsuit challenging mifepristone’s approval was brought by the Alliance Defending Freedom, which was also involved in the Mississippi case that led to Roe v. Wade being overturned. At the core of the lawsuit is the allegation that the FDA’s initial approval of mifepristone was flawed because the agency did not adequately review safety risks. Mifepristone has been used by millions of women over the past 23 years, and complications from mifepristone occur at a lower rate than problems in wisdom teeth removal, colonoscopies and other routine procedures, medical groups have recently noted.